Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Does postmastectomy radiotherapy benefit breast cancer patients with 1-3 positive lymph nodes?

Date

20 Dec 2015

Session

Poster presentation 2

Presenters

Tae Ryool Koo

Citation

Annals of Oncology (2015) 26 (suppl_9): 16-33. 10.1093/annonc/mdv519

Authors

T.R. Koo1, E.Y. Kang2, J.H. Kim2, S.Y. Park2, S.W. Kim2, I.A. Kim1

Author affiliations

  • 1 Radiation Oncology, Seoul National University Hospital, 110-744 - Seoul/KR
  • 2 Breast Care Center, Seoul National University Bundang Hospital, Seongnam-si/KR
More

Resources

Abstract 549

Aim/Background

The benefit of postmastectomy radiotherapy (PMRT) in breast cancer patients with 1-3 positive lymph nodes (LNs) is unclear. We compared outcomes and evaluated prognostic factors in patients with 1-3 positive LNs having PMRT or not.

Methods

We retrospectively reviewed records of breast cancer patients who had mastectomy in our institution between 2003 and 2011. The patients with neoadjuvant systemic therapy were excluded. A total of 120 patients with pN1 disease were identified. PMRT was given in 24 patients (PMRT group) and not in 96 patients (non-PMRT group). PMRT encompassed chest wall and supraclavicular fossa, and median dose was 50.4 (range, 50–60) Gy in daily dose of 1.8 (range, 1.8-2) Gy. The primary end-point was 5-year disease-free survival (DFS). To explore the influence of LN status on DFS, we included the ratio of positive LNs (LNR). The cut-off value of LNR was selected as 0.1, which showed maximum difference in DFS between PMRT and non-PMRT groups.

Results

The median follow-up times were 60.8 (range, 8.6-129.5) months for entire patients, and 59.9 (range, 25.2-115.6) months and 63.1 (range, 8.6-129.5) months for PMRT and non-PMRT groups, respectively. At 5-year, locoregional recurrence-free survival, distant metastasis-free survival, DFS, and overall survival rates were 97.1%, 92.2%, 91.3%, and 97.4%, respectively. Between PMRT and non-PMRT groups, 5-year DFS rates were not different, 89.4% and 91.8% (p = 0.722). Comparing with non-PMRT group, PMRT group had more unfavorable characteristics, such as 2-3 positive LNs (75.0% vs. 43.8%, p = 0.006) and higher LNR (66.7% vs. 34.4%, p = 0.004). In the univariate analysis, the higher LNR showed a trend of worse DFS (p = 0.087), while the number of positive LNs or other variables did not have significant associations with DFS. According to the multivariate analysis, the higher LNR was associated with a trend of worse DFS (p = 0.107).

Conclusions

In this study, PMRT group showed comparable outcomes with non-PMRT group, though more patients with unfavorable tumor characteristics underwent PMRT. The LNR rather than the absolute number of involved LNs showed a possibility to be considered as a useful parameter to make a decision to perform PMRT in breast cancer patients with 1-3 positive LNs.

Clinical trial identification

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings